Balchem Reports $290.7 Million in Fiscal Q3 Sales, $1.57 Adjusted Diluted EPS

Balchem posted $290.658 million in net sales and $1.57 in adjusted diluted EPS for fiscal third-quarter 2026, ended Sept. 30, with sales higher than a year earlier.

Net earnings totaled $46.728 million, while adjusted net earnings were $50.350 million. GAAP diluted EPS was $1.46.

Compared with the year-earlier quarter, net sales rose 8.6% and net earnings increased 16%. Adjusted EBITDA climbed 12.4% to $80.297 million.

Operating cash flow was $69.8 million, and free cash flow was $57.9 million. Balchem reports results across Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.

“Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA,” said Chairman, President and CEO Ted Harris.